SEC Filing Summary: SAB Biotherapeutics, Inc. (SABS)
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by SAB Biotherapeutics, Inc. on June 18, 2026. The Company is incorporated in Delaware and its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols SABS and SABSW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
At the Annual Meeting, 59,349,534 shares were present, representing approximately 76.12% of the 77,966,409 shares entitled to vote, constituting a quorum. Shareholders approved two proposals:
- Proposal 1: Election of Class II Directors. Dr. David Zaccardelli, Katie Ellias, David Link, and Andrew Moin were elected to serve three-year terms. Notably, while all directors received majority support, significant votes were withheld for David Link (4,271,175) and Andrew Moin (4,197,394). Broker non-votes totaled 10,994,436 for all director nominees.
- Proposal 2: Ratification of Auditors. Shareholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was overwhelmingly in favor with 59,319,363 votes for, 3,373 against, and 26,798 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the meeting results.
Investor Verification Checklist
- Verify the specific reasons for the high number of votes withheld for directors David Link and Andrew Moin compared to their peers.
- Confirm the total number of broker non-votes (10,994,436) and their impact on the effective voting power of the shareholder base.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Monitor the Company's status as an emerging growth company and any implications for future reporting standards.